Olga E. Akbasheva

Olga E. Akbasheva

Auto-generated profile, based on publicly available information

Olga E. Akbasheva

Siberian State Medical University

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
DBDaria Borodkina
Daria Borodkina
OAOlga Akbasheva
Olga Akbasheva
OBOlga Barbarash
Olga Barbarash
Determination of the impact of visceral obesity and epicardial adipose tissue thickness on stimulating growth factor levels during hospitalization for myocardial infarction is of potential importance for predicting outcomes and assessing the development of cardiofibrotic changes associated with maladaptive myocardial remodeling. In this study, we aimed to investigate the relationships between epicardial adipose tissue thickness, adipokine profiles, and the stimulating growth factor 2/interleukin-33 signaling system during hospitalization for myocardial infarction, and with the cardiac fibrosis extent 1-year post-MI in patients with visceral obesity. Eighty-eight patients with myocardial infarction were grouped based on their visceral obesity. Serum leptin, adiponectin, stimulating growth factor 2, and interleukin-33 levels were measured on days 1 and 12 and at 1 year. The epicardial adipose tissue widths and the cardiac fibrosis areas were measured on day 12 and at 1 year. Visceral obesity was associated with epicardial adipose tissue thickness increases, adipokine imbalances, elevated leptin levels, and lower adiponectin levels during early hospitalization, and cardiac fibrosis development. Patients without visceral obesity had higher interleukin-33 and stimulating growth factor 2 levels during early hospitalization and lower cardiac fibrosis rates. Epicardial adipose tissue thickness was positively associated with cardiac fibrosis prevalence and interleukin-33 levels and negatively associated with stimulating growth factor 2 levels. The cardiac fibrosis extent was negatively associated with interleukin-33 levels and positively associated with stimulating growth factor 2 levels. Increases in epicardial adipose tissue thickness are associated with cardiac fibrosis development 1-year post-myocardial infarction and are higher in patients with visceral obesity. The metabolic activity of the epicardial adipose tissue is associated with elevated interleukin-33 and reduced stimulating growth factor 2 levels.

17 March 2016 in Diabetology & Metabolic Syndrome
Verified
Journal Article
Open access
PDF file
OBOlga Barbarash
Olga Barbarash
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
EBEkaterina Belik
Ekaterina Belik
AKAlexander Kokov
Alexander Kokov
This study aimed to evaluate the markers of insulin resistance and adipokine status in patients with visceral obesity during hospitalization following myocardial infarction (MI) and assess the disturbances of carbohydrate metabolism present 1 year after MI onset. 94 male patients with MI were recruited. The exclusion criteria were as follows: age less than 50 or greater than 80 years, the presence of type 2 diabetes mellitus (T2DM), and a prior history of pronounced renal failure.Obesity types were defined according to body mass index (BMI), waist circumference (WC) and visceral adipose tissue (VAT) area. Glucose, insulin, adiponectin, leptin, and insulin resistance (IR) index were measured on days 1 and 12 after the onset of MI. New-onset type 2 diabetes was assessed 1 year after MI onset. According to computed tomography assessments of all study patients, 69 % of patients with MI suffered from visceral obesity. The VAT area was more closely associated with the risk of developing type 2 diabetes compared with the obesity parameters, BMI and WC. Patients with a VAT area greater than 130 cm2 had a 3.6-fold higher risk of developing type 2 diabetes. The presence of IR and hyperleptinemia increased the risk of developing diabetes in the post-MI period 3.5 and 3.7 times, respectively, in patients with visceral obesity compared with patients without visceral obesity. Visceral obesity is associated with IR, a 5.7-fold increase in leptin levels and a high risk of developing type 2 diabetes 1 year after MI onset.

24 December 2018 in Bulletin of Siberian Medicine
Verified
Journal Article
Open access
PDF file
EUEvgenya Uchasova
Evgenya Uchasova
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
YDYulia Dyleva
Yulia Dyleva
OAO. E. Akbasheva
O. E. Akbasheva
Visceral adipose tissue is an important predictor of cardiovascular diseases, which carry more risk than total fat accumulation. Epicardial fat, a special form of visceral fat deposited around the heart, is considered an important predictor of the risk of cardiovascular disease, taking into account the production and release of adipocytokines. Recently, the number of experimental and clinical data proving the physiological and metabolic significance of epicardial fat is increasing. The thickness and volume of epicardial adipose tissue (EAT) have a strong correlation with obesity, impaired fasting glucose, insulin resistance, metabolic syndrome and atherosclerosis. Moreover, it is now clear that the connection between EAT and the heart is regulated by complex two directional pathways, since not only adipokines regulate cardiac function, but the heart affects EAT via paracrine signaling. Further study of the molecular mechanisms regulating the interaction between the heart and EAT will improve our understanding of the role of the latter in cardiac physiology and the development of disease mechanisms.

19 January 2017 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
OAOlga Akbasheva
Olga Akbasheva
VMVera Matveeva
Vera Matveeva
OBOlga Barbarash
Olga Barbarash
Cytokines play an significant role in regulating non-specific inflammatory response involved in many pathological processes. The current study tested the hypothesis that myocardial infarction in patients with obesity can lead to increased production of proinflammatory cytokines and unfavorable course of the pathological process. The study recruited 232 male patients with ST-elevated myocardial infarction. The mean age of the patients was 58.7 (52.2-69.9) years. All the patients were assigned to two groups according to the computed tomography findings: 1 (n = 160) patients with visceral obesity (VO), and 2 (n = 72) patients without VO. Interleukins were measured in blood serum on days 1 and 12 after MI. All patients with MI demonstrated elevated levels of proinflammatory markers and reduced anti-inflammatory markers in the in-hospital period. The results suggested that among all studied inflammatory markers IL-6 (OR 1.9; 95% CI (1.6–2.8) and CRP (OR 1.3; 95% CI (1.1–1.8) were closely related to VO. One year after MI adverse cardiovascular outcome frequently occurred in patients with VO. There were two cardiac deaths (3.1%), 6 cases (9.3%) of recurrent MI, 19 cases (29.6%) of repeated hospitalizations for unstable angina, whereas only 2 patients without VO (6.6%) were hospitalized for unstable angina. The results of the logistic regression analysis demonstrated that IL-6, IL-12, and IL-10 had the highest predictive value for occurrence of adverse cardiovascular events in patients with VO. Cytokine profile in MI patients with VO is characterized by an imbalance caused by elevated pro-inflammatory interleukins and decreased anti-inflammatory interleukins. Obesity in patients was associated with a marked increase in IL-6 and CRP levels.

20 November 2015 in Russian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
OAO. E. Akbasheva
O. E. Akbasheva
DBD. A. Borodkina
D. A. Borodkina
VKV. N. Karetnikova
V. N. Karetnikova
YDYu. A. Dyleva
Yu. A. Dyleva
OBOlga Barbarash
Olga Barbarash
Цель. Изучить маркеры инсулинорезистентности и адипокинового статуса у пациентов с висцеральным ожирением в динамике госпитального периода инфаркта миокарда и оценить нарушения углеводного обмена через год после перенесенного заболевания.Материал и методы. Обследовано 94 пациента с инфарктом миокарда (ИМ), тип ожирения определяли по индексу массы тела (ИМТ), объемуталии (ОТ) и площади висцеральной жировой ткани (ВЖТ). На 1-е и 12-е сутки госпитализации определяли содержание глюкозы, инсулина, адипонектина, лептина и индекс инсулинорезистентности (ИР). В течение года после перенесенного заболевания оценивали новые случаи манифестации сахарного диабета второго типа (СД). Результаты. По данным компьютерной томографии 69% пациентов с ИМ имеют висцеральное ожирение (ВО). В отличие от таких показателей ожирения как И МТ и ОТ, площадь ВЖТ наиболее тесно связана с риском развития СД 2 типа. Показано, что если у пациента площадь ВЖТ составляет более 130 см , то вероятность развития СД 2 типа повышается в 3,6 раза. Наличие ИР и гиперлептинемии у пациентов с ВО увеличивает риск развития СД в отдаленном постинфарктном периоде, соответственно, в 3,5 и 3,7 раза, по сравнению с пациентами без ВО.Заключение. Висцеральное ожирение связано с ИР, увеличением содержания лептина в 5,7 раза и высоким риском развития СД 2 типа через год после перенесенного ИМ.

1 December 2017 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
ОГОльга Викторовна Груздева
Ольга Викторовна Груздева
EUEvgenya Uchasova
Evgenya Uchasova
YDYulia Dyleva
Yulia Dyleva
OAOlga Akbasheva
Olga Akbasheva
VKVictoria Karetnikova
Victoria Karetnikova
OBOlga Barbarash
Olga Barbarash
Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction Olga Gruzdeva,1 Evgenya Uchasova,1 Yulia Dyleva,1 Olga Akbasheva,2 Victoria Karetnikova,1 Aleksandr Shilov,1 Olga Barbarash1 1Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russia; 2State Budget Educational Institution of Higher Professional Education, Siberian State Medical University, Russian Federation Ministry of Health, Tomsk, Russia Background: Cardiovascular diseases and type 2 diabetes mellitus (T2DM) may have common developmental mechanisms associated with lipid metabolism disorders. Dyslipidemia and progression of atherosclerosis in people with T2DM are accompanied by an increase in cardiovascular mortality. This study examined the dose-dependent action of atorvastatin on carbohydrate metabolism and adipokine status in patients within 12 months after myocardial infarction (MI).Methods: A total of 156 male MI patients who had received atorvastatin 20 mg/day (78 patients) or 40 mg/day (78 patients) starting from day 1 of onset were enrolled. Glucose, insulin, C-peptide, resistin, adiponectin, and ghrelin levels were measured at baseline, day 12, and months 3 and 12. Patients were monitored for new incidences of T2DM for 12 months after MI.Results: For acute phase MI, patients had moderate insulin resistance, hyperglycemia, and hyperinsulinemia, high leptin and resistin levels, and low ghrelin and adiponectin levels. Atorvastatin 20 mg/day was more effective at correcting the imbalances. Patients taking atorvastatin 40 mg/day (group 2) following MI showed increases in levels of glucose, insulin, and C-peptide and insulin resistance progression after 12 months of therapy, as evidenced by increased quantitative insulin sensitivity check index scores and detection of new T2DM cases.Conclusion: Atorvastatin improved adipokine profiles and ghrelin levels, with low doses showing more significant effects. Atorvastatin dose prescribed for MI patients should take into account the degree of insulin resistance and adipokine status. Keywords: statin, myocardial infarction, inflammation, adipokine, resistin